Physiologically based pharmacokinetic and biopharmaceutics modeling (PBPK/PBBM) are transforming drug development by reducing reliance on time-consuming and costly in vivo studies and accelerating decision-making. These modeling approaches provide a mechanistic framework to support drug development from discovery through formulation.
In this webinar, Deanna Mudie, Senior Principal Scientist of PBPK R&D at Simulations Plus, will explain how high-throughput PBPK using ADMET Predictor® can rapidly predict systemic exposure using in silico derived properties or minimal in vitro data, enabling more informed compound selection and reducing the need for extensive preclinical testing. She’ll also cover how in later stages, PBBM using GastroPlus® integrates drug and formulation properties with gastrointestinal physiology to simulate in vivo performance — supporting formulation optimization, food-effect prediction, and the development of clinically relevant dissolution specifications.
Whether you’re a modeler, formulation scientist, or development strategist, this session will provide real-world case studies demonstrating how integrating PBPK and PBBM across the drug development continuum can enhance productivity, reduce in vivo study requirements, and enable smarter, faster decisions.
Robert Wenslow is a seasoned drug development scientist with a strong background in pharmaceutical characterization. He has extensive experience in all solid-state research issues relating to the pharmaceutical industry. He and his team at Crystal Pharmatech will work with you to speed up your drug discovery, research, and development needs at a containable cost.
He has 26 years of experience in pharmaceutical development, including 14 years at Merck with various leadership positions. He headed the API group — Center for Materials Science and Engineering in the Merck Manufacturing Division. He established the first analytical research group in Ireland for Merck, while also maintaining direct responsibilities for overseeing the solid-state NMR facility. He obtained a Ph.D. degree in Chemistry from Pennsylvania State University.
Deanna Mudie is a recognized leader in oral drug formulation development and physiologically based biopharmaceutics modeling (PBBM) with over 20 years of experience spanning academia, large pharmaceutical companies, CDMOs, and software development.
As a Senior Principal Scientist at Simulations Plus, she plays a pivotal role in advancing cutting-edge modeling solutions that drive innovation in drug development. Her expertise includes PBBM, biorelevant in vitro dissolution testing, and oral formulation design and manufacturing, making her a key contributor to optimizing drug performance and accelerating regulatory approvals.
Dr. Mudie holds a PhD in Pharmaceutical Sciences and a BSE in Chemical Engineering from the University of Michigan.